DB00615ApprovedInvestigationalSmall moleculeDrugs for Treatment of TuberculosisRifamycin Antimycobacterial
Rifabutin is an antibiotic used to treat mycobacterium avium complex disease in patients with HIV.
- Mechanism
- Curator reviewed
Rifabutin acts via the inhibition of DNA-dependent RNA polymerase in gram-positive and some gram-negative bacteria, leading to a suppression of RNA synthesis and cell death.
- Primary indication
- For the prevention of disseminated Mycobacterium avium complex (MAC) disease in patients with advanced HIV infection.Curator reviewed · 6 structured indications
- Formula / weight
- C46H62N4O11 · 847.0047 g/mol (avg)
- First approval
- Canada, 2003 · United States, 1992
- Also known as
- Ansamicin · Ansamycin
- Code names
- BV100 · LM-427
- Brand names
Resolves to
Structure
InChIKey
ATEBXHFBFRCZMA-VXTBVIBXSA-NSMILESCO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(C(O)=C3C)C(=O)C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)=C1NC3(CCN(CC3)CC(C)C)N=C21Transporters
What you can answer from here — as of September 23, 2026
6Protein targetsEach mapped to UniProt, with action and pharmacological actionListed above
1TransporterSubstrate / inhibitor direction, not just membershipListed above
Which drugs share a target with Rifabutin, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account